Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Has Consensus Price Target of $63.40

Key Points

• Maze Therapeutics has a consensus “Buy” rating from 13 analysts, with nine buys, three strong buys and one sell. The average 12-month price target is $63.40, substantially above the stock’s reported $27.18 price.
• Recent analyst targets range from $46 to $110, while insiders sold 134,849 shares worth approximately $3.58 million over the past 90 days. The disclosed sales were made to cover tax withholding obligations tied to equity awards.
• Maze reported quarterly EPS of -$0.76, in line with estimates, and analysts expect a full-year EPS loss of $2.72. The clinical-stage biotech is developing precision medicines, including MZE001, an oral treatment candidate for Pompe disease.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) has earned a consensus recommendation of "Buy" from the thirteen brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and three have issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $63.40.

Several analysts recently weighed in on the stock. Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. BTIG Research reaffirmed a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Tuesday, September 22nd. HC Wainwright reiterated a "buy" rating and issued a $110.00 price target on shares of Maze Therapeutics in a research report on Thursday, September 24th. Wedbush restated an "outperform" rating and set a $48.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. Finally, Citigroup assumed coverage on Maze Therapeutics in a research note on Wednesday, September 23rd. They issued a "buy" rating and a $50.00 price objective on the stock.

Insider Transactions at Maze Therapeutics

In other news, insider Atul Dandekar sold 3,243 shares of the company's stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $84,350.43. Following the transaction, the insider directly owned 32,316 shares of the company's stock, valued at $840,539.16. This represents a 9.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Courtney Phillips sold 2,012 shares of the business's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12. Following the sale, the insider owned 7,007 shares of the company's stock, valued at $182,252.07. This trade represents a 22.31% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 134,849 shares of company stock valued at $3,582,240. 5.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Maze Therapeutics

Large investors have recently added to or reduced their stakes in the business. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Maze Therapeutics during the 2nd quarter worth approximately $48,000. Royal Bank of Canada lifted its holdings in shares of Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company's stock valued at $61,000 after purchasing an additional 1,383 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Maze Therapeutics in the second quarter valued at approximately $80,000. Caitong International Asset Management Co. Ltd bought a new stake in Maze Therapeutics during the fourth quarter worth $145,000. Finally, Persistent Asset Partners Ltd purchased a new stake in Maze Therapeutics in the 2nd quarter valued at $200,000.

Maze Therapeutics Trading Up 0.6%

Shares of NASDAQ:MAZE opened at $27.18 on Thursday. The business's 50 day simple moving average is $27.02 and its 200 day simple moving average is $28.40. Maze Therapeutics has a 1 year low of $21.95 and a 1 year high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The company has a market capitalization of $1.51 billion, a P/E ratio of -10.79 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). On average, research analysts anticipate that Maze Therapeutics will post -2.72 EPS for the current fiscal year.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze's lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.